ABBV - AbbVie Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
+1.33 (+1.83%)
As of 2:03PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close72.39
Bid73.70 x 800
Ask73.71 x 800
Day's Range72.06 - 73.78
52 Week Range62.66 - 96.60
Avg. Volume11,668,533
Market Cap108.99B
Beta (3Y Monthly)0.70
PE Ratio (TTM)26.91
Earnings DateN/A
Forward Dividend & Yield4.28 (5.91%)
Ex-Dividend Date2019-10-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • AC Immune to Earn Milestone From Lilly for Alzheimer's Drug

    AC Immune to Earn Milestone From Lilly for Alzheimer's Drug

    AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.

  • Benzinga

    Notable Insider Buys In The Past Week: AbbVie, Kraft Heinz And More

    Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. Kraft Heinz Co (NASDAQ: KHC) saw two directors buying some shares last week. Also note a large sale of shares this past week by a beneficial owner.


    Top Insider Buys Highlight for the Week of Sept. 20

    Insiders invest in Kraft Heinz, Dominion Energy, Keurig Dr Pepper and AbbVie Continue reading...

  • Are Insiders Buying AbbVie Inc. (NYSE:ABBV) Stock?
    Simply Wall St.

    Are Insiders Buying AbbVie Inc. (NYSE:ABBV) Stock?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • Gilead, AbbVie Are Innovative, but May Be Underappreciated

    Gilead, AbbVie Are Innovative, but May Be Underappreciated

    Companies need to demonstrate they can be successful in new therapeutic areas Continue reading...


    AbbVie Stock Is Falling Because Investors Hate the Allergan Deal. The Vice Chairman Bought Up Shares.

    Laura Schumacher made her first open-market purchase of stock, paying $1.8 million for shares of the biopharmaceutical firm.

  • The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK

    The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK

    The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK

  • Top Analyst Reports for AbbVie, Union Pacific & CSX

    Top Analyst Reports for AbbVie, Union Pacific & CSX

    Top Analyst Reports for AbbVie, Union Pacific & CSX

  • U.S. Senators urge FTC to scrutinize multi-billion dollar pharma mergers

    U.S. Senators urge FTC to scrutinize multi-billion dollar pharma mergers

    Bristol-Myers Squibb's $74 billion buyout of Celgene Corp and AbbVie Inc's $63 billion bid for troubled smaller rival Allergan Plc were among the largest deals announced this year. The deals proposed by AbbVie and Bristol-Myers raise significant antitrust issues, the senators wrote, calling on the FTC to "take appropriate action" to protect consumers from mergers that may threaten competition, raise drug prices or reduce patient access to essential medications. "This industry consolidation is occurring against a backdrop of ever rising prescription drug spending... It is more important than ever that the FTC take appropriate action to protect consumers," Klobuchar wrote in the letter signed by senators Bernie Sanders, Kamala Harris, Elizabeth Warren and Cory Booker among others.

  • Novartis Announces New Data on Spondylitis Drug Cosentyx

    Novartis Announces New Data on Spondylitis Drug Cosentyx

    Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.

  • AbbVie (ABBV) Gains As Market Dips: What You Should Know

    AbbVie (ABBV) Gains As Market Dips: What You Should Know

    AbbVie (ABBV) closed the most recent trading day at $70.59, moving +0.11% from the previous trading session.

  • Moody's

    AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's euro notes; stable outlook

    Moody's Investors Service ("Moody's") assigned a Baa2 rating to the new senior unsecured euro-denominated notes offering of AbbVie Inc. ("AbbVie"). The are no changes to AbbVie's existing ratings including the Baa2 senior unsecured long-term ratings and the Prime-2 commercial paper rating. AbbVie's Baa2 rating reflects the company's large scale, high margins and robust cash flow, all supported by the lucrative Humira franchise.

  • Dividend Growth ETFs for Long Term Investors

    Dividend Growth ETFs for Long Term Investors

    Dividend growth ETFs hold companies with solid balance sheets and rising earnings.

  • Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland

    Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland

    Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.

  • Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

    Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

    About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's planned $63 billion purchase of Botox maker Allergan Plc . The combination of two of the world's biggest pharmaceutical companies, which was announced in June, would feature a portfolio that includes the world's top-selling medicine - AbbVie's rheumatoid arthritis drug Humira - as well as its cancer drugs and Allergan's blockbuster wrinkle treatment, Botox, and big-selling dry eye drug Restasis.


    Gilead Tops List of Most Innovative Drug Companies

    Index ranks ability of pharma companies to bring drugs from early testing to market and make them successful Continue reading...

  • Humira Sales Will Crash To $3 Billion — Why AbbVie Stock Got An Upgrade
    Investor's Business Daily

    Humira Sales Will Crash To $3 Billion — Why AbbVie Stock Got An Upgrade

    Revenue from AbbVie's inflammation treatment Humira will crash to $3 billion annually by 2025, an analyst said Thursday — but he upgraded AbbVie stock ahead of its Allergan buyout.


    Buy AbbVie Stock, Because Its Deal for Allergan Just Might Work, Analyst Says

    AbbVie’s acquisition of Allergan will create a new company churning out $20 billion in free cash flow a year, and that makes it worth buying, UBS’ Navin Jacob said Thursday.


    AbbVie Stock Rises After UBS Upgrades To Buy

    AbbVie shares rose in Thursday trading after the drugmaker's stock was upgraded to buy from neutral at UBS. Analyst Navin Jacob also lowered the price target to $79 from $85. "We upgrade AbbVie to buy because its acquisition of Allergan leads to a Newco generating $20 billion-plus of annual free cash flow growing to a highly compelling, 9% free cash flow yield in '23E (year of Humira's U.S. patent expiry)," Jacob wrote in a Sept. 12 note.

  • 4 Big Drugmakers Boasting Impressive Oncology Pipelines

    4 Big Drugmakers Boasting Impressive Oncology Pipelines

    We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

  • Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

    Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

  • 10 Healthcare Stocks to Buy Despite the Headlines

    10 Healthcare Stocks to Buy Despite the Headlines

    The past several weeks have been raucous ones for all stocks, but particularly wild ones for healthcare stocks. Not only is the future of the nation's healthcare market in flux, drug companies are facing an inordinate degree of litigation, and biopharma names have dished out plenty of R&D updates … some good, some bad.By and large, the bearish market-wide tide and the weakness healthcare stocks have suffered has become something of an opportunity. A handful of these names have become bargains and are ripe for recoveries. * 10 Stocks to Sell in Market-Cursed September To that end, here's a rundown of ten healthcare stocks to buy, even if they're surrounded by bad news and grim headlines. Some are familiar, and others are not. All of them, however, arguably boast more potential than risk at this time, even if not all of them have yet to reach their worst-case-scenario price.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (JNJ)Source: Sundry Photography / Johnson & Johnson (NYSE:JNJ) has arguably faced the worst and most alarming headlines of late, facing not one but two major legal battles.The first one of course is its liability linked to asbestos contained in its talcum powder sold under the brand name Johnson & Johnson. The other? Some states' attorneys general are suggesting J&J was culpable for what's turned into a nationwide opioid addiction epidemic. A closer inspection of both matters reveals the ultimate liability for both may not be as dire as is currently believed.Though the state of Oklahoma recently won a case that will fine Johnson & Johnson $572 million for allowing opioid abuse to become a "public nuisance," that figure was smaller than shareholders had feared, and may point to similarly small figures in other state-level cases.As for its talcum powder woes, the company is prevailing in some state courts, and losing in others. With the exception of one case in California, the awards granted in cases it has lost have been relatively modest. AbbVie (ABBV)Source: Piotr Swat/Shutterstock AbbVie (NYSE:ABBV) shares are down nearly 50% from their early 2018 high, reaching another multi-month low in August.The underpinnings for that weakness aren't difficult to deduce. Aside from an increasingly tough battle to defend its patents on breadwinner drug Humira, the decision to acquire Allergan (NYSE:AGN) hasn't been a particularly popular one with shareholders.ABBV stock owners have also been disappointed by a couple of major busts on the R&D front. The company's work in turning Rova-T into a successful lung cancer treatment, for instance, was thrown away when AbbVie ended phase 3 trials after it failed to create meaningful results. * 7 "Boring" Stocks With Exciting Prospects The punishment, so to speak, hasn't fit the crime though. AbbVie now quietly rates as one of the top healthcare stocks to buy at its now greatly-lowered price thanks to a dividend yield of 6.44% that's reasonably well protected, and a forward-looking P/E of only 7.. CVS Health (CVS)Source: Shutterstock Admittedly, it remains unclear which sliver of the healthcare market will be the one to bear the brunt of any cost-cutting reform. Hospitals and insurers are just as targeted as pharmacy names like CVS Health (NYSE:CVS), which is a key part of the reason CVS stock has been nearly cut in half since the middle of 2015.That doubt is rooted in a paradigm shift that isn't likely to happen, however, or at least not as abruptly as some are fearing.Case in point: Just days after announcing plans to eliminate the rebate enjoyed by pharmacies and pharmacy benefits managers, President Donald Trump backpedaled. Although it's not clear where the pressure for the reversal came from, clearly someone is in the industry's corner.In the meantime, CVS is preparing for all contingencies. It now owns health insurer Aetna and is tiptoeing into the medical device arena. In July the company announced it was beginning trials of an at-home kidney dialysis solution. Bausch Health Companies (BHC)Source: n4i Via FlickrYou may recognize the name as one that has specialized in eye care for a long time now. And Bausch -- Bausch + Lomb, to be precise -- certainly still makes contact lenses and eye-surgery products. This is not the Bausch Health Companies (NYSE:BHC) in question, however. While Bausch Health owns and operates Bausch + Lomb, the Bausch that has earned a spot on a list of healthcare stocks to buy is actually the company formerly known as Valeant Pharmaceuticals.That name will also ring a bell for most investors … although not a good one. That's the company that went on an aggressive acquisition spree, planning on buying specialty drugs to then mark their price up to unnecessarily expensive levels.In addition to public outcry, congress got involved, ultimately forcing then-CEO Michael Pearson out, and forcing new CEO Joseph Papa to rebuild everything the company is, and does. * 7 Best Stocks That Crushed It This Earnings Season Surprise! He's doing it. Though it's still erratic and somewhat unpredictable, sales are expected to grow 1.6% this year, and 3% next. It's not much, but it's enough to drive real earnings growth. Intercept Pharmaceuticals (ICPT)Source: Shutterstock Intercept Pharmaceuticals (NASDAQ:ICPT) isn't an easy name to own. Although the biopharma outfit is driving major sales growth with its chronic liver disease drug Ocaliva, the company's a one-trick pony that's still losing money. Last quarter's top line of $66.3 million -- mostly Ocaliva -- was up 53% year-over-year, but still let Intercept book an operating loss of $63.6 million and a total net loss of $71.4 million.In this case though, the company's fiscal trajectory against the backdrop of an obesity epidemic translates into a bright future. Intercept Pharmaceuticals is also working on a nonalcoholic steatohepatitis (NASH) drug that takes aim at what is expected to be the leading cause of liver failure by 2020. That under-served market could be worth $50 billion, if not more, leaving this company amazingly well-positioned for growth. Pfizer (PFE)Source: Manuel Esteban/Shutterstock Stripping out last month's 20% stumble, Pfizer (NYSE:PFE) has been a pretty good bet in recent years. Thing is, the aspects that have made PFE stock one of the best healthcare stocks to buy for a long while now are still in place. That is, a diverse portfolio that doesn't lean too much on any one drug. No one product accounts for more than 10% of the company's total revenue.The selloff, for the record, was spurred by the decision to sell its 'off patent' drug business operating as Upjohn to rival Mylan (NASDAQ:MYL). The downside of that exit appears to be fully priced in now though, and then some. * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off In the meantime, a $500 million investment in a North Carolina manufacturing facility pushes the company deeper into gene therapy waters, which may offer more upside than existing business lines. PRA Health Sciences (PRAH)Source: Shutterstock When investors thinks of healthcare stocks, PRA Health Sciences (NASDAQ:PRAH) isn't a name that generally comes to mind. Indeed, most investors may have never even heard of it.The one who have heard of it, meanwhile, might be wishing they hadn't. Even with this year's choppy rebound effort, shares of the contract research organization are still down 19%.A bet against PRA Health Sciences hasn't been a particularly wise bet in the grand scheme of things. Contracted research is a key part of the future of healthcare, as outsourcing R&D becomes the more cost-effective solution.PRA Health has the numbers to prove it, too. This year's expected 6.4% revenue growth isn't jaw-dropping, but it's reliable, as will be next year's projected 8.4% top-line growth. Better still, that progress is driving even greater profit growth. Per-share profits are expected to reach $5.03 this year, up from last year's $4.28, and grow 13% to $5.68 per share next year. Alexion Pharmaceuticals (ALXN)Source: Shutterstock Last week, Alexion Pharmaceuticals (NASDAQ:ALXN) shares started what would end up becoming a 14% plunge. The selloff may not be done yet either. The prod? Amgen (NASDAQ:AMGN) is challenging Alexion's patent on Soliris, which is used to treat a trio of rare diseases. It makes up the bulk of Alexion's sales.It's an alarming development, although not one that's necessarily devastating. Right or wrong, running patent-based interference meant to disrupt other companies is the new norm within the pharmaceuticals arena, and there's not necessarily any assurance that Amgen will prevail. The chatter that Amgen could make an acquisition bid for Alexion still has its merits as well. * 10 Buy-and-Hold Stocks to Own Forever In the meantime, the forward-looking P/E of 9.9 suggests ALXN is priced cheaply enough to survive any profit-sharing agreement that Amgen may end up pursuing instead of an outright legal victory. Cigna (CI)While pharmacies and pharmaceuticals are certainly vulnerable to any sweeping overhauls in the way the United States healthcare industry works, it's not like the insurers are particularly well-shielded. Cigna (NYSE:CI), for instance, is down more than 30% since its early 2018 high on concerns about insurers' futures, after they all had a pretty good run between 2013 and 2017.Not everyone is concerned about one of a myriad of 'maybes' that could impact Cigna though.Alliance Bernstein analyst Lance Wilkes is one of those optimists. He recently upgraded CI stock while it was down, re-rating it at an "Outperform," explaining "We are increasing our price target and rating on [Cigna] based upon earnings growth driven from deal synergies and its low valuation, which we believe offset our [long term] concerns on policy risks and strategic position."CI stock is trading at only 14 times its trailing earnings, and only 8.2 times next year's expected profits. Eli Lilly (LLY)Source: Shutterstock Finally, add drugmaker Eli Lilly (NYSE:LLY) to your list of healthcare stocks to buy despite a recent wave of bad news.For Lilly, that's mostly been spurred by pipeline and portfolio questions. In March it announced it would launch a cheaper alternative to its own top-selling Humalog insulin, and early this year it decided to acquire Loxo Oncology at an unpopularly frothy premium.There's a reason that slide suffered during the first half of the year has started to reverse course beginning in early August. Not only did Lilly win the outcome it wanted in a recent arbitration claim regarding a collaboration it entered with Adocia to develop rapid-acting insulin, a phase 3 trial of its oral JAK inhibitor Baricitinib as a therapy for atopic dermatitis showed tremendous promise with last month's update.They're little victories that can really add up in investors' heads.As of this writing, James Brumley held no position in any of the aforementioned securities. You can learn more about James at his site,, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell in Market-Cursed September * 7 of the Worst IPO Stocks in 2019 * 7 Best Stocks That Crushed It This Earnings Season The post 10 Healthcare Stocks to Buy Despite the Headlines appeared first on InvestorPlace.

  • AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

    AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

    AbbVie (ABBV) closed the most recent trading day at $66.70, moving -1.36% from the previous trading session.